429 related articles for article (PubMed ID: 26150437)
41. A cross sectional study comparing traditional risk factors with N-terminal pro-BNP in high risk groups for cardiovascular disease in Trinidad, West Indies.
Shivananda Nayak B; Teelucksingh S; Jagessar A; Maharaj S; Maharaj N
Diabetes Metab Syndr; 2013; 7(1):8-11. PubMed ID: 23517788
[TBL] [Abstract][Full Text] [Related]
42. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study.
Shlipak MG; Ix JH; Bibbins-Domingo K; Lin F; Whooley MA
Am J Med; 2008 Jan; 121(1):50-7. PubMed ID: 18187073
[TBL] [Abstract][Full Text] [Related]
43. High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer's disease: the FINRISK Study.
Tynkkynen J; Hernesniemi JA; Laatikainen T; Havulinna AS; Salo P; Blankenberg S; Zeller T; Salomaa V
J Neurol; 2017 Mar; 264(3):503-511. PubMed ID: 28039523
[TBL] [Abstract][Full Text] [Related]
44. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
[TBL] [Abstract][Full Text] [Related]
45. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
[TBL] [Abstract][Full Text] [Related]
46. N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease.
Wannamethee SG; Welsh P; Lowe GD; Gudnason V; Di Angelantonio E; Lennon L; Rumley A; Whincup PH; Sattar N
J Am Coll Cardiol; 2011 Jun; 58(1):56-64. PubMed ID: 21700090
[TBL] [Abstract][Full Text] [Related]
47. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.
Natriuretic Peptides Studies Collaboration ; Willeit P; Kaptoge S; Welsh P; Butterworth AS; Chowdhury R; Spackman SA; Pennells L; Gao P; Burgess S; Freitag DF; Sweeting M; Wood AM; Cook NR; Judd S; Trompet S; Nambi V; Olsen MH; Everett BM; Kee F; Ärnlöv J; Salomaa V; Levy D; Kauhanen J; Laukkanen JA; Kavousi M; Ninomiya T; Casas JP; Daniels LB; Lind L; Kistorp CN; Rosenberg J; Mueller T; Rubattu S; Panagiotakos DB; Franco OH; de Lemos JA; Luchner A; Kizer JR; Kiechl S; Salonen JT; Goya Wannamethee S; de Boer RA; Nordestgaard BG; Andersson J; Jørgensen T; Melander O; Ballantyne ChM; DeFilippi Ch; Ridker PM; Cushman M; Rosamond WD; Thompson SG; Gudnason V; Sattar N; Danesh J; Di Angelantonio E
Lancet Diabetes Endocrinol; 2016 Oct; 4(10):840-9. PubMed ID: 27599814
[TBL] [Abstract][Full Text] [Related]
48. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study.
Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E
Circulation; 2011 May; 123(19):2101-10. PubMed ID: 21536998
[TBL] [Abstract][Full Text] [Related]
49. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis.
Rodseth RN; Biccard BM; Le Manach Y; Sessler DI; Lurati Buse GA; Thabane L; Schutt RC; Bolliger D; Cagini L; Cardinale D; Chong CP; Chu R; Cnotliwy M; Di Somma S; Fahrner R; Lim WK; Mahla E; Manikandan R; Puma F; Pyun WB; Radović M; Rajagopalan S; Suttie S; Vanniyasingam T; van Gaal WJ; Waliszek M; Devereaux PJ
J Am Coll Cardiol; 2014 Jan; 63(2):170-80. PubMed ID: 24076282
[TBL] [Abstract][Full Text] [Related]
50. Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes.
Colombo M; Looker HC; Farran B; Agakov F; Brosnan MJ; Welsh P; Sattar N; Livingstone S; Durrington PN; Betteridge DJ; McKeigue PM; Colhoun HM
Atherosclerosis; 2018 Jul; 274():182-190. PubMed ID: 29793175
[TBL] [Abstract][Full Text] [Related]
51. Increased serum level of N-terminal Pro-B-type natriuretic peptide as a possible biomarker of cardiovascular risk in psoriatic patients.
Pietrzak A; Bartosinska J; Blaszczyk R; Chodorowska G; Brzozowski W; Hercogova J; Donica H; Lotti T
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1010-4. PubMed ID: 24735175
[TBL] [Abstract][Full Text] [Related]
52. Comparison of B-type natriuretic peptide and NT proBNP as predictors of survival in patients on high-flux hemodialysis and hemodiafiltration.
Sivalingam M; Suresh M; Farrington K
Hemodial Int; 2011 Jul; 15(3):359-65. PubMed ID: 21624043
[TBL] [Abstract][Full Text] [Related]
53. NT-proBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf Recall Study.
Kara K; Lehmann N; Neumann T; Kälsch H; Möhlenkamp S; Dykun I; Broecker-Preuss M; Pundt N; Moebus S; Jöckel KH; Erbel R; Mahabadi AA
Int J Cardiol; 2015 Mar; 183():155-61. PubMed ID: 25666125
[TBL] [Abstract][Full Text] [Related]
54. Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels.
Carrasco-Sánchez FJ; Pérez-Calvo JI; Morales-Rull JL; Galisteo-Almeda L; Páez-Rubio I; Barón-Franco B; Aguayo-Canela M; Pujol-De la llave E
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):115-21. PubMed ID: 24522084
[TBL] [Abstract][Full Text] [Related]
55. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism.
Ogard CG; Engelmann MD; Kistorp C; Nielsen SL; Vestergaard H
Clin Endocrinol (Oxf); 2005 Nov; 63(5):493-8. PubMed ID: 16268799
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function.
Horii M; Matsumoto T; Uemura S; Sugawara Y; Takitsume A; Ueda T; Nakagawa H; Nishida T; Soeda T; Okayama S; Somekawa S; Ishigami K; Takeda Y; Kawata H; Kawakami R; Saito Y
J Cardiol; 2013 Jun; 61(6):410-6. PubMed ID: 23618914
[TBL] [Abstract][Full Text] [Related]
57. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator.
Khera A; Budoff MJ; O'Donnell CJ; Ayers CA; Locke J; de Lemos JA; Massaro JM; McClelland RL; Taylor A; Levine BD
Circulation; 2018 Oct; 138(17):1819-1827. PubMed ID: 30354651
[TBL] [Abstract][Full Text] [Related]
58. Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study.
Brutsaert EF; Biggs ML; Delaney JA; Djoussé L; Gottdiener JS; Ix JH; Kim F; Mukamal KJ; Siscovick DS; Tracy RP; de Boer IH; deFilippi CR; Kizer JR
Metabolism; 2016 Oct; 65(10):1489-97. PubMed ID: 27621184
[TBL] [Abstract][Full Text] [Related]
59. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.
Melander O; Newton-Cheh C; Almgren P; Hedblad B; Berglund G; Engström G; Persson M; Smith JG; Magnusson M; Christensson A; Struck J; Morgenthaler NG; Bergmann A; Pencina MJ; Wang TJ
JAMA; 2009 Jul; 302(1):49-57. PubMed ID: 19567439
[TBL] [Abstract][Full Text] [Related]
60. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial.
Velders MA; Wallentin L; Becker RC; van Boven AJ; Himmelmann A; Husted S; Katus HA; Lindholm D; Morais J; Siegbahn A; Storey RF; Wernroth L; James SK;
Am Heart J; 2015 Jun; 169(6):879-889.e7. PubMed ID: 26027627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
